This mind-blowing study revealed how berberine lowers LDL cholesterol through a mechanism that’s completely different from ...

Patients receiving concomitant PCSK9 inhibitor therapy experienced greater LDL cholesterol reductions, exceeding 50% during ...

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is highly expressed in adult hepatocytes. PCSK9 binds to and promotes the degradation of the low-density lipoprotein (LDL) receptor, thereby ...

Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...

Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an effective alternative to injections of PCSK9 inhibitors to lower low-density ...

Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials RAHWAY, N.J.--(BUSINESS WIRE)- ...

PITTSBURGH, Oct. 30, 2025 – An international team led by a University of Pittsburgh School of Medicine scientist has created a first-of-its-kind resource to identify those with a genetic risk for ...

Please provide your email address to receive an email when new articles are posted on . Lerodalcibep further reduced LDL vs. placebo in well-treated patients with HeFH. More than 85% of the ...

Patients with severe hypercholesterolemia who are unresponsive to a number of lipid-lowering therapies, including a PCSK9 inhibitor and high-dose statin, can have a significant reduction in ...

CARDIO—AEROBIC ACTIVITIES like walking, running, swimming, and cycling—not only reduces total cholesterol, LDL, vLDL and ...